Study Summary
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Eligible Conditions
- Endometrial Cancer
- Endometrial Carcinoma Stage III
- Stage III Endometrial Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: up to 3 years
up to 3 years
Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Participants with Endometrial Cancer
1 of 1
Experimental Treatment
28 Total Participants · 1 Treatment Group
Primary Treatment: Participants with Endometrial Cancer · No Placebo Group · Phase < 1
Participants with Endometrial CancerExperimental Group · 3 Interventions: Carboplatin, Paclitaxel, Intensity-modulated radiation therapy · Intervention Types: Drug, Drug, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~7230
Paclitaxel
2011
Completed Phase 4
~6440
Intensity-modulated radiation therapy
2006
Completed Phase 3
~1230
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,834 Previous Clinical Trials
588,338 Total Patients Enrolled
19 Trials studying Endometrial Cancer
4,508 Patients Enrolled for Endometrial Cancer
Kaled Alektair, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Eligibility Criteria
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Patients must have been recently diagnosed with one of the following histological subtypes of endometrial carcinoma: Endometrioid, Serous, Clear Cell, Dedifferentiated/Undifferentiated, Mixed Epithelial, Adenocarcinoma Not Otherwise Specified or Carcinosarcoma.
Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy and pelvic lymph node surgical assessment (e.g
Patients must be diagnosed with FIGO (2009) stage IIIA or higher according to surgical staging.
Patients must give permission to take MSK-IMPACT part A and are encouraged to agree to both parts A and C.
You are at least 18 years old.
Patients must have a KPS score of 70 or greater.
Your neurological function is assessed to have minimal signs of neuropathy.
You have no gross signs of illness remaining after surgery.
You have not undergone radiation therapy, chemotherapy or hormone therapy for the treatment of endometrial cancer.
There is no current infection requiring antibiotics, except for a straightforward urinary tract infection.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments